Search OTLC
Oncotelic Therapeutics, Inc.
OTC · CIK 908259
Last close0.02
Daily change+0.00 (0.00%)
10 Years gain-96.72%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
OTLC · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
24.0Momentum
0.0Acceleration
0.0Confidence
71.0Annual Revenue4
Quarterly Revenue10
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet8.8 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 1396.2795 percentage points.
Heavy share dilution · HIGHDiluted share count increased 393.9101%.
Key Metrics
Revenue Growth TTM-82.57%OK
Revenue CAGR 3Y-23.44%OK
Gross Margin100%OK
Operating Margin-1,805.94%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-3.26%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0xOK
Diluted Share Growth 1Y393.91%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$3.19M | -$1.38M | n/a | n/a | n/a | n/a | -1.61% | 422.23M |
| 2025 FY Dec 31, 2024 | n/a | $0.00 | -$3.58M | -$740,277.00 | n/a | n/a | n/a | n/a | -23.16% | 404.4M |
| 2024 FY Dec 31, 2023 | $70,000.00 | $70,000.00 | -$6.65M | -$1.32M | n/a | 100% | -9,497.16% | n/a | -31.56% | n/a |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$9.72M | -$1.45M | n/a | n/a | n/a | n/a | -56.26% | 457.3M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$9.13M | -$4.43M | n/a | n/a | n/a | n/a | -75.34% | 303.08M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $320,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-21-029599, 0001493152-21-020818 |
| Revenue Growth TTM | -82.57% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-21-029599, 0001493152-21-020818 |
| Revenue CAGR 3Y | -23.44% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001641172-25-004846 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001641172-25-004846 |
| Gross Profit CAGR 3Y | -23.44% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001641172-25-004846 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-21-029599, 0001493152-22-010094 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001493152-21-029599, 0001493152-21-020818 |
| Operating Margin | -1,805.94% | Operating Income / Revenue | OK | 0001493152-21-029599, 0001493152-21-020818 |
| ROIC | -3.26% | NOPAT / Average Invested Capital | OK | 0001493152-21-029599, 0001493152-22-010094 |
| Net Debt / CFO | 0x | Net Debt / CFO | OK | 0001493152-21-029599, 0001493152-21-020818 |
| Current Ratio | 0.08x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001493152-21-029599, 0001493152-21-020818 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |